TriangleFOR PATIENTS · SOURCE READING
Immunotherapy
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Mantle-cell-specific source passages within broader non-Hodgkin lymphoma sections Only selected blocks explicitly name mantle cell lymphoma. Full owning sections include other lymphomas and must not be relabeled mantle-cell-only.
Context from the original source
Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.
Source links and citations
This intact source passage also discusses another lymphoma. Retained to preserve distinctions such as established use versus investigation; it is not a mantle-cell-only statement.
CAR T-cell therapy: The patient's T cells (a type of immune system cell) are changed so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy (such as axicabtagene ciloleucel or tisagenlecleucel) is used to treat large B-cell lymphoma that has not responded to treatment. CAR T-cell therapy is being studied to treat mantle cell lymphoma that has relapsed or not responded to treatment.
Preserved source evidence · Independent clinical review pending · Not medical advice